Tags

Type your tag names separated by a space and hit enter

Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome.
World J Surg. 1993 Jul-Aug; 17(4):433-8.WJ

Abstract

It is often difficult to localize gastrinomas in patients with Zollinger-Ellison syndrome (ZES). We have developed a new useful method, the selective arterial secretin injection test (SASI test), for localizing gastrinomas in patients with ZES. The SASI test first determines the arteries feeding the gastrinomas and then locates the gastrinomas. In 12 patients with ZES, the SASI test clearly localized the gastrinomas, while results obtained with computed tomography or portal venous blood sampling had a positive predictability of less than 10%. Following localization with the SASI test, curative resection of gastrinomas was successfully performed on 7 patients who consented to the operation. Each of 3 patients had one duodenal submucosal microgastrinoma and one or more metastatic lymph node; the other 4 patients had 2 to 10 microgastrinomas or large gastrinomas in the duodenum or the pancreas. All 7 patients, who exhibited negative responses with a postoperative secretin test, have been completely cured from 3 months to 4 years postoperatively. The usefulness of the SASI test for preoperative evaluation is demonstrated by the fact that it gives a 100% positive predictability rate as well as a 100% negative predictability rate. Hence the SASI test precisely locates functioning gastrinomas.

Authors+Show Affiliations

First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8362526

Citation

Imamura, M, and K Takahashi. "Use of Selective Arterial Secretin Injection Test to Guide Surgery in Patients With Zollinger-Ellison Syndrome." World Journal of Surgery, vol. 17, no. 4, 1993, pp. 433-8.
Imamura M, Takahashi K. Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World J Surg. 1993;17(4):433-8.
Imamura, M., & Takahashi, K. (1993). Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World Journal of Surgery, 17(4), 433-8.
Imamura M, Takahashi K. Use of Selective Arterial Secretin Injection Test to Guide Surgery in Patients With Zollinger-Ellison Syndrome. World J Surg. 1993 Jul-Aug;17(4):433-8. PubMed PMID: 8362526.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. AU - Imamura,M, AU - Takahashi,K, PY - 1993/7/1/pubmed PY - 1993/7/1/medline PY - 1993/7/1/entrez SP - 433 EP - 8 JF - World journal of surgery JO - World J Surg VL - 17 IS - 4 N2 - It is often difficult to localize gastrinomas in patients with Zollinger-Ellison syndrome (ZES). We have developed a new useful method, the selective arterial secretin injection test (SASI test), for localizing gastrinomas in patients with ZES. The SASI test first determines the arteries feeding the gastrinomas and then locates the gastrinomas. In 12 patients with ZES, the SASI test clearly localized the gastrinomas, while results obtained with computed tomography or portal venous blood sampling had a positive predictability of less than 10%. Following localization with the SASI test, curative resection of gastrinomas was successfully performed on 7 patients who consented to the operation. Each of 3 patients had one duodenal submucosal microgastrinoma and one or more metastatic lymph node; the other 4 patients had 2 to 10 microgastrinomas or large gastrinomas in the duodenum or the pancreas. All 7 patients, who exhibited negative responses with a postoperative secretin test, have been completely cured from 3 months to 4 years postoperatively. The usefulness of the SASI test for preoperative evaluation is demonstrated by the fact that it gives a 100% positive predictability rate as well as a 100% negative predictability rate. Hence the SASI test precisely locates functioning gastrinomas. SN - 0364-2313 UR - https://www.unboundmedicine.com/medline/citation/8362526/Use_of_selective_arterial_secretin_injection_test_to_guide_surgery_in_patients_with_Zollinger_Ellison_syndrome_ L2 - http://www.diseaseinfosearch.org/result/7600 DB - PRIME DP - Unbound Medicine ER -